COVID-19：小野薬品､フオイパンに注力：ONO5334開発を見送り（動画）：
Therapeutic Drugs for Novel Coronavirus Infection (COVID-19)：
新型冠状病毒感染（COVID-19）治疗药物的开发
COVID-19：
小野薬品工業：
7月30日、化合物「ONO5334」の開発を見送ると発表しました。
英科学誌ネイチャーで新型コロナウイルスの治療薬として有望と報告されていました。
「フオイパン」の開発：
新型コロナ向けでは、すい炎治療薬「フオイパン」の開発に注力します。
2020年6月に臨床試験（治験）を開始。
フオイパンは、既に感染抑制効果やヒトへの投与の安全性に関する知見があります。
現在国内でフェーズ1の治験を実施しています。
ONO5334のウイルス感染抑制効果：
ONO5334のウイルス感染抑制効果を検討した結果、フオイパンに比べ効果が低いと判断しました。
小野薬品は、骨粗しょう症の治療薬としてONO5334の開発を進めていた。
しかし、競合環境を考慮して2012年に開発を中止。
英科学誌の報告では、ONO5334が新型コロナ感染に関わる酵素などへの阻害作用を持つことから、治療薬としての可能性があるとされています。
日本経済新聞
https://r.nikkei.com/article/DGXMZO62110800Q0A730C2000000?s=4
Development of Therapeutic Drugs for Novel Coronavirus Infection (COVID-19)
July 30, 2020
Ono Pharmaceutical Co., Ltd.
announced today that it has decided not to enter into the development of ONO-5334, as a therapeutic drug for novel coronavirus infection (COVID-19),
which was reported as one of the promising compounds that suppresses the growth of novel coronavirus in human iPSC-derived pneumocyte-like cells in the English scientific journal “Nature” on July 24. In addition,
ONO will further promote the development of a proteinase inhibitor,
Foipan® (generic name: camostat mesilate) Tablets (“Foipan”) under the clinical development for the treatment of COVID-19.
While ONO-5334 had been developed by ONO as a drug candidate for the treatment of osteoporosis based on its inhibitory effect on cathepsin K, its development in the osteoporosis area was discontinued in 2012 comprehensively taking into consideration the competitive situation in the osteoporosis area and changes in the environment.
ONO-5334 has an inhibitory effect on cathepsins including cathepsin L, which is known as a potential enzyme involved in coronavirus infection.
According to the report in Nature,
ONO-5334 was identified as a potent compound to inhibit viral replication in several cells suggesting its possibility as a therapeutic drug for COVID-19. Also, it is known that the proteolytic enzyme TMPRSS2 is greatly involved in major infections of the COVID-19 causative virus SARS-CoV-2 in the lungs or airways.